The renin-angiotensin system is one of a number of inter/inked mechanisms regulating vascular resistance and blood volume. Under certain conditions it may become a predominant factor in maintaining vascular tone. Knowledge about these conditions (sodium depletion, mineralocorticoid deficiency, renovascular hypertension and iatrogenic hyperreninaemic states) is important for the safe and effective use of drugs which inhibit the renin-angiotensin system. Measurements of plasma renin activity are useful in the diagnostic assessment of hypertensive patients with hypokalaemia or evidence of renal artery stenosis. They may also have a place in the management of refractory or dialysis-resistant hypertension. Their use in the selection of antihypertensive therapy for the individual patient is controversial. Sequential measurements of plasma renin are helpful in analysing states of electrolyte depletion, and in titrating therapy for Addison's disease.
From the discovery of the renal pressor substance renin by Tigerstedt and Bergman in 1898 1 to the present time, the gradual unravelling of the intricacies of the reninangiotensin system has been closely linked with growth in knowledge about hypertension. In 1934, Goldblatt and his colleagues produced sustained elevation of blood pressure in dogs by constricting both renal arteries or by constricting the renal artery on one side and removing the kidney on the other. 2 In 1940 groups, headed by Braun-Menendez 3 and Page,4 showed independently that the renal pressor substance was a proteolytic enzyme, dependent for its biological actions upon production of the octapeptide angiotensin 11, which has a uniquely potent constrictor action on arteriolar smooth muscle. More recently the advent of inhibitors of the renin-angiotensin system has allowed a more complete analysis of the role of this system in the pathogenesis of various forms of hypertension in animals and man.
From time to time, during the development of this history, the renal pressor system was assigned by some the role of the dominant support mechanism for cardiovascular function in health or disease. While there was a measure of truth in these assertions, it has become clear from studies in anephric man and experimental models that the renin-angiotensin system is not always crucial to the maintenance of arteriolar tone and blood pressure in health, in hyptertension nor in other circulatory disorders. Rather, as one of a number of inter linked control systems concerned with the regulation of peripheral vascular resistance and blood volume, it is able, under certain circumstances and for perhaps a limited time, to become a preponderant influence in maintaining the level of blood pressure. The circumstances, which include sodium depletion and other forms of hyperreninism, are important for the anaesthetist to recognise, for they may set the scene for unexpectedly strong hypotensive responses to drugs with inhibitory effects on the renin-angiotensin system.
BASIC PHYSIOLOGY
The cells which produce renin are located in the juxtaglomerular apparatus, a complex of cells in the glomerular hilum where the afferent and efferent arterioles and the macula densa region of the distal tubule are in close contiguity. The granular juxtaglomerular cells, which synthesise, store and release renin, are smooth muscle cells found mostly in the media of the afferent arteriole. Under circumstances of juxtaglomerular hyperplasia, the mesangial cells of the apparatus may also develop a reninsecretory function. 5 Renal sympathetic nerve endings innervate the granular juxtaglomerular cells.
The morphological relationships are important from a functional viewpoint. In their location along the afferent arteriole the granular cells may be influenced physically by renal perfusion pressure such that a fall in pressure can evoke an increase in renin release. 6 They appear to be influenced directly also by the sodium concentration of luminal fluid in the macula densa region, for microperfusion studies have shown that a rise in sodium chloride concentration passing the macula densa stimulates renin release. 7 Stimulation of the renal sympathetic nerves causes renin release. 8 The receptors mediating this effect and also the excitatory effect of circulating catecholamines are (3-adreno-receptors which are involved also in the inhibitory activity of (3-adrenoceptor-blocking drugs upon renin release. Factors effecting renin release are shown in Table 1 .
Once released into the circulation, renin immediately implements the sequence of steps which lead to the generation of angiotensin, but a proportion may lodge in the walls of blood vessels throughout the general circulation. 9
BASIC BIOCHEMISTRY
The main constituents of the reninangiotensin system are renin, renin substrate, 
I.
Fall in renal perfusion pressure.
2.
Rise in NaCl concentration in macula densa segment of distal tubule.
3.
Sympathetic stimulation operating through f3-adrenoceptors.
4.
Whole-body sodium depletion.
5.
Hypokalaemia.
6.
Upright posture.
7.
Fall in circulating angiotensin II level.
angiotensin I (decapeptide), converting enzyme, angiotensin 1I (octapeptide), angiotensin III (heptapeptide) and angiotensin receptors. In addition, the system is an important humoral trophic factor in the control of the secretion of aldosterone. Renin This is a glycoprotein with a molecular weight of 40,000 and is synthesised and stored in the renal juxtaglomerular cells. It acts in the general circulation and possibily within the blood vessel walls as a proteolytic enzyme which cleaves its substrate at a leucyl-Ieucine bond to split off the decapeptide, angiotensin I, at the amino-terminal end. Renin exists in at least two forms. Some of the renin in plasma is biologically inactive, but may become active after acid exposure or cold storage. As renin in plasma is commonly assayed by incubation in vitro with its substrate, often after freezing and thawing or even acidification of the plasma samples, serious confusion has arisen in the past in determining the true levels of active renin in ViVO.1O Renin-like enzymes have been found in important amounts in a number of tissues including the salivary glands, chorion and brain; local renin-angiotensin mechanisms in these tissues have been suspected but their existence is not generally accepted.
Renin substrate
This is a glycoprotein of molecular weight 59,000 produced in the liver and existing in large amounts in the Cl'2-globulin fraction of the plasma. In human plasma it is the amount of renin circulating rather than the amount of substrate which constitutes the major ratelimiting factor in the generation of angiotensin in vivo. However, the amount of substrate Anaesthesia and Intensive Care, Vol. 1 J, No. 4, November, 1983 produced during pregnancy or in women taking oral contraceptives may increase sufficiently above normal to affect the rate of angiotensin production. Plasma substrate levels are also increased by bilateral nephrectomy, but are reduced by adrenalectomy.
Angiotensin I and converting enzyme
Angiotensin I has little or no pressor activity of itself, but requires conversion to angiotensin II for effect. This takes place principally in the lung, but the fact that an appreciable amount of conversion has been demonstrated to occur in peripheral vascular beds too ll may be important, for it strengthens the concept that angiotensin may be produced locally in the blood vessel wall by the intramural action of renin without actually entering the circulation. 12 Converting enzyme, also called kininase I1, is a zinc metalloenzyme which splits off the two C-terminal amino acids of angiotensin I to form the octapeptide angiotensin n, and also inactivates bradykinin.
Serum converting enzyme levels are elevated in patients with sarcoidosis and Gaucher's disease, but the sites of excess production of the enzyme are uncertain. 13
Angiotensin Il and III
Angiotensin II has a diversity of biological effects which, in general, tend to elevate or maintain the level of blood pressure. It has a direct vasoconstrictor effect, some 50 times more potent than noradrenaline, when injected intravenously. Its half-life is short, approximately 30 seconds. 14 Angiotensin acts directly on the renal circulation causing falls in blood flow, glomerular filtration rate and sodium excretion. As a trophic hormone for aldosterone biosynthesis, it also leads to sodium retention through stimulation of aldosterone production by the adrenal cortex. It releases catecholamines from the adrenal medulla and stimulates autonomic ganglia. It also inhibits the release of neurotransmitter by an agonist effect on presynaptic receptors. Within the central nervous system, it produces complex effects on sympathetic and parasympathetic outflow by actions on the area postrema of the hind brain and also stimulates drinking and antidiuretic hormone release.
Angiotensin III is a heptapeptide resulting from further degradation of angiotensin H. It Anaesthesia and Intensive Care, Vol. 11. No. 4, November, 1983 has a potency for adrenal steroidogenesis similar to that of the octapeptide but its direct pressor effect is about 25070 that of angiotensin Il.
Angiotensin receptors
Experiments with labelled angiotensin n have shown a direct relationship between specific binding of the hormone to the arterial wall and adrenal cortex, and its biological effects. IS . 16 Some aspect of the interaction between the hormorne and its specific receptors appears to modulate the effect of the reninangiotensin system upon arterial blood pressure such that when the system is activated the pressor response to a given plasma angiotensin 11 level is lessened. Thus, for example, during stimulation of the system by sodium depletion there is a decreased vascular response to angiotensin. It is uncertain whether this modulation reflects changes in the number of receptors or, alternatively, the degree of prior receptor occupancy by endogenous angiotensin II formed both in the plasma and locally within vascular walls. 17 Aldosterone This is a potent mineralocortical hormone, the biosynthesis and secretion of which is under the control of the circulating concentrations of angiotensin n (and/or angiotensin Ill), ACTH, sodium and potassium. It is metabolised mainly in the liver. Aldosterone has its principal effect on blood pressure by influencing the extent of sodium reabsorption in the renal tubules. Hyperaldosteronism is characterised by sodium retention, potassium depletion and hypertension. However, there is recent evidence to suggest that aldosterone may increase vascular tone directly, by binding to specific receptor sites in arterial smooth muscle cells and influencing their permeability to cations,18 or by decreasing the extraneuronal uptake of catecholamines. 19
CONTROL OF RENIN RELEASE
In addition to the basic physiological mechanisms controlling the release of renin into the circulation (i.e. the renal baroreceptor, the macula dens a sodium sensor and the renal sympathetic nerves) a wide range of pathophysiological and pharmacological stimuli can influence circulating renin levels ( Table 1) . Whole body depletion of sodium or fluid volume causes pronounced stimulation of renin release. The afferent pathways for these effects are multiple and are not well documented. The sensitivity to minor changes in volume status may be exquisite in some situations. 20 Upright posture 21 and tilting 22 are well-defined stimuli to renin release. The subject of pharmacologic alteration of renin release is vast and has been reviewed recentiy.23 Thus, no attempt will be made to provide a detailed description of drug interactions with the renin-angiotensin system. However, a summary list of agents that can increase or decrease renin release and the circulating levels of plasma angiotensin appears in Table 2 .
The importance of knowing that general anaesthesia is associated with altered renin release bears mainly on the subject of interpreting the results of animal experiments reported in the literature. It is clear that, irrespective of the agent used, a surgical plane of anaesthesia stimulates renin release. This has been shown to be a consequence of autonomic excitation in the case of ether or urethane, whereas the increase in renin release produced by halothane could not be blocked by Decrease I. a-adrenergic agonists clonidine* methyldopa L-dopa 2. fJ-adrenergic antagonists atenolol* metoprolol * propranolol* timolol* oxprenolol * prindolol labetalol 3.
Prostaglandin synthesis inhibitors indomethacin 4.
Mineralocorticoids fludrocortisone* DOCA* practolo1. 23 The strong but variable effects of anaesthesia on the renin-aldosterone system must be borne in mind as a limiting factor when considering human studies; for example, if it is planned to monitor plasma renin levels following operative repair of renal artery stenosis. Vasodilator drugs, in particular diazoxide, are probably the most potent known pharmacological stimuli to renin release. Although part of their action is mediated through the hypotension they produce, with consequent reflex sympathetic stimulation and fall in renal perfusion pressure, a direct intrarenal effect upon the juxtaglomerular apparatus is likely. 24 Diazoxide and the loop diuretic, frusemide, are the agents most frequently used in stimulating renin release for clinical diagnostic purposes.
Understanding the potential for certain drugs to stimulate renin release is critical for the safe therapeutic use of inhibitors of the reninangiotensin system. If these inhibitors are used when renin levels are high, and are playing an important role in the maintenance of vascular tone, then catastrophic hypotension may occur. At the same time, the use of angiotensin inhibitors themselves may stimulate renin release. This occurs in part by the reflex effects of the hypotension produced, and in part by the uncoupling of negative feedback inhibition of angiotensin II upon renin release. 25 The significance of pharmacological reduction of renin release lies mainly in the confusion it can cause in interpreting plasma renin levels for diagnosis. However, interactions between renin-suppressive and renin-stimulating agents can be used advantageously; accordingly, in planning stepped-care therapy of hypertension, betablockers are advocated for use with vasodilator drugs partly because of their ability to depress circulating renin and angiotensin concentrations. However, there is little evidence that the inherent antihypertensive activity of beta-blockers, used alone, relates to renin inhibition.
It is the effect of the sodium retention caused by mineralocorticoids on renin release that explains the low plasma renin levels characteristic of adrenocortical hyperfunction, particularly that associated with primary aldosteronism.
MEASUREMENTS OF PLASMA RENIN
The measurement of renin within plasma depends upon the ability of the enzymic Anaesthesia and Intensive Care, Vol. 11, No. 4, November, 1983 Decrease (a) with hypertension primary aldosteronism other mineralocorticoid syndromes (b) wilh or without hypertension hyporeninaemic hypoaldosteronism (c) with hypotension dysautonomia hormone to generate angiotensin I from endogenous substrate ("plasma renin activity") or from this plus an excess of added substrate ("plasma renin concentration"). The amount of angiotensin I generated is determined, usually by radioimmunoassay, and the result expressed per unit time of incubation. Apart from factors such as the temperature and pH of the specimen and the conditions of its collection and storage, the state of sodium balance of the subject may critically affect the answer obtained. Thus, the interpretation of results in disease requires comparison with control data, obtained from normal subjects on the same level of dietary sodium intake as the patient. Alternatively, reference can be made to a nomogram, relating plasma renin values to concurrent urinary sodium excretion rate,26 whereby the results from patients may be categorised as low, normal or high irrespective of the patients' dietary sodium habit. Similar considerations apply in the measurement of circulating plasma angiotensin II. Sampling of plasma for measurement of plasma renin concentration or activity may be carried out from a peripheral vein or by percutaneous retrograde catheterisation of the renal veins. The latter procedure is of considerable interest in predicting the surgical curability of renovascular hypertension, in which (as detailed below) appreciable changes may occur in renal venous renin levels and in the ratio of results from the affected and contralateral kidneys.27
ALTERATIONS IN PLASMA RENIN ACTIVITY
(PRA) IN DISEASE STATES Conditions associated with an increase or decrease in plasma renin activity are shown in Table 3 .
Unilateral main renal artery stenosis and segmental renal ischaemia caused by branch renal artery stenosis are generally associated with an increase in PRA in the renal venous blood on the affected side, together with a rise in peripheral PRA and a fall in PRA in contralateral renal venous blood (due to reflex suppression of renin release on that side). However, these findings are not invariable, for renal parenchymal damage causing sodium retention may counter stimulation of renin release by ischaemia. Bilateral renal artery stenosis, likewise, may be associated with normal PRA.
In accelerated hypertension, arteriolar damage in the kidney may occur as part of a vicious circle of renal microvascular ischaemia, hyperreninaemia and progressively more severe hypertension. Resistance to normal therapy leads to the use of large doses of diuretics or vasodilators which may further increase PRA. In end-stage renal failure, removal of excess body fluid by dialysis may reveal that hypersecretion of renin is playing a part in sustaining hypertension.
Renin-secreting tumours (Wilm's tumors, hypernephromas or benign haemangiopericytomas) are a rare but important cause of hypertension and high PRA. 2S The increased catecholamine release caused by phaeochromocytomas may increase PRA. Oral contraceptives stimulate production of renin substrate and this can cause increase of PRA, although renin release is normal or suppressed.
There is an important group of disorders in which blood pressure is normal or low, and PRA is increased due to sodium depletion together with a contracted extracellular fluid space. The level of PRA is a guide both in diagnosis and management of these disorders. This applies particularly to purgative and diuretic abuse, Addison's disease or other, rarer, mineralocorticoid deficiency syndromes and Bartter's syndrome. Measurements of PRA are of great value in controlling mineralocorticoid substitution therapy in Addison's disease 29 and isolated hypoaldosteronism. 30 Bartter's syndrome is an uncommon disorder of obscure aetiology which causes very high levels of PRA, hyperaldosteronism and hypokalaemia. 31 There is no oedema, and hypotension occurs rather than hypertension. The course of the disorder in adults is benign and it usually comes to attention because of an intercurrent condition which exaggerates the potassium depletion, producing muscular weakness or cardiac arrhythmia. Diagnosis is made by hormonal studies and renal biopsy (which shows hyperplasia of the juxtaglomerular apparatus). Bartter' s syndrome may be simulated by chronic purgative or diuretic abuse.
Decreased PRA is a key diagnostic feature in primary aldosteronism (Conn's syndrome). This important, potentially curable form of hypertension is usually associated with a solitary adrenocortical adenoma (less commonly, adrenal hyperplasia or carcinoma). The diagnostic features include: hypertension with hypokalaemia, urinary potassium loss inappropriate to the degree of hypokalaemia, low PRA with subnormal response to sodium depletion and erect posture, increased plasma aldosterone and urinary aldosterone excretion with loss of normal responses to sodium depletion and sodium loading. Hyporeninaemic hypoaldosteronism is an uncommon clinical entity seen in elderly subjects, often in the presence of diabetes mellitus or renal impairment, and is associated with hyperkalaemia and metabolic acidosis. 32 ROLE OF MEASUREMENTS OF RENIN-ANGIOTENSIN FUNCTIONS IN DIAGNOSIS There are well-defined diagnostic indications for the determination of PRA in certain hypertensive states, as outlined above. In summary, these are situations in which there is evidence of renal artery stenosis (e.g. epigastric bruit, lateralising features in the intravenous pyelogram), severe or treatment-resistant hypertension, or hypokalaemia. PRA should be measured in suspected Bartter's syndrome. Sequential measurements of PRA may help to clarify the basis of states of fluctuating electrolyte depletion, such as diuretic or purgative abuse.
Anaesthesia and Intensive Care, Vol. J I, No. 4, November, 1983 The infusion of angiotensin inhibitors intravenously may constitute a useful means of measuring PRA and circulating angiotensin levels indirectly. Certain problems, however, have arisen from interpreting the response of arterial blood pressure to administration of these inhibitors as an indicator of the functional status of the renin-angiotensin system. Angiotensin analogues (e.g. saralasin) have a variable degree of partial agonist effect, and converting enzyme inhibitors (e.g. teprotide, captopril) may lower blood pressure in part by blocking kininase II activity.
Much controversy has surrounded the question of whether measurements of reninangiotensin functions are worth while in the management of hypertensive disease overall. There has been considerable enthusiasm in North America for such measurements as a tool in helping to predict which type of antihypertensive drug may be most suitable for the individual patient. 33 The trend in Australia and Europe in this matter has been towards scepticism. However, the advent of new, more specific and less toxic inhibitors of the reninangiotensin system, which have proved most effective in antihypertensive therapy, is keeping the controversy very much alive.
